Anant Raj Limited has announced its financial and operational performance for Q3 FY25, showcasing remarkable growth across all key metrics.

The company reported a 36% year-on-year (YoY) increase in revenue from operations, reaching INR 544 crores, while EBITDA surged by 45% YoY to INR 143 crores. Profit Before Tax (PBT) grew by 53% YoY to INR 132 crores, and Profit After Tax (PAT) jumped 55% YoY to INR 110 crores. Notably, 9M FY25 revenue, EBITDA, and PAT have already surpassed the full-year performance of FY24, demonstrating sustained business momentum.

Anant Raj Limited has also made significant strides in debt reduction, with net debt declining to INR 54 crores in Q3 FY25 from INR 96 crores in Q2 FY25.

On the data center front, the company has operationalized a 6 MW IT load facility at Manesar, with plans to scale up to 28 MW IT load across Manesar and Panchkula. In a strategic move, Anant Raj launched ‘Ashok Cloud’, Bharat’s own sovereign cloud platform, in collaboration with Orange Business. Initially offering Infrastructure as a Service (IaaS), the company aims to expand into colocation services, tapping into the growing demand for data localization and AI-driven cloud solutions.

In the real estate segment, the company has begun construction of The Estate Residences and Anant Raj Ashray – 2, Tirupati, with work progressing at full speed. Additionally, the handover process for Birla Navya Phase 1 has commenced, while Birla Navya Phase 4 is set for launch in Q4 FY25.

Anant Raj remains committed to delivering excellence across real estate and digital infrastructure, reinforcing its position as a leader in India’s evolving business landscape.

4 February 2025, Mumbai: Alembic Pharmaceuticals Limited reported its consolidated financial results for the third quarter ended 31st December, 2024.

Financial Highlights

• Net Sales increased by 4% to Rs.1693 Crores.
• EBITDA up 1% to Rs. 271 Crores
• EBITDA Margin at 16% of Sales
• Net Profit at Rs.138 Crores

Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said. “In the current quarter, we faced market headwinds in the acute segment. However, other key therapies in our specialty business continued to outpace the market growth. To strengthen field force efficiency, we have enhanced Automation and AI, to upscale execution. This Transition has partly impacted quarter growth. We are confident to show a robust growth trajectory going forward. The US Business posted significant volume growth and the Ex-US markets continued to expand steadily. API Business is still under significant pricing pressure.”

India Branded Business

• India Branded Business grew 3% to Rs. 614 crores for the quarter.
• Animal Health business grew 22% for the quarter with basket of strong brands driving outperformance.
• Specialty therapies recorded growth of 6%.
• 3 launches during the quarter. New launches continue to do well along with promising future launches across key segments.

International Business

• US Generics grew 10% to Rs. 521 Crores for the quarter.
• 2 Launches in the US market during the quarter.
• Ex-US International Generics grew 10% to Rs. 299 Crores for the quarter.
• 7 ANDA approvals received during the quarter, 219 Cumulative ANDA approvals.

API Business

Particulars	Q3 FY25	Q3 FY24	% Change	9M FY25	9M FY24	% Change
Formulation
India	614	596	3%	1795	1697	6%
USA Ex- US	521 299	474 272	10% 10%	1449 868	1308 790	11% 10%
API	259	289	(10%)	791	916	(14%)
Total	1693	1631	4%	4902	4712	4%